BIOMAT Database Logo BIOMAT Database Logo

A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia. 2005

Farideh Miraki-Moud, and Ashley B Grossman, and Michael Besser, and John P Monson, and Cecilia Camacho-Hübner
Department of Endocrinology, 51-53 Bartholomew Close, St. Bartholomew's Hospital, London EC1A 7BE, United Kingdom.

BACKGROUND Non-islet cell tumor hypoglycemia (NICTH) results from the hypersecretion of pro-IGF-II by a large, usually mesenchymal tumor. Detection of pro-IGF-II in serum is a potential tumor marker in these patients. OBJECTIVE The aim of this study was to validate a rapid and reliable method for determining serum pro-IGF-II. METHODS Serum samples from 16 patients with NICTH were studied. METHODS The main outcome measure was serum concentration of pro-IGF-II determined by immunoblot analysis of pro-IGF-II and mature IGF-II after 16.5% tricine-SDS-PAGE, which was compared with pro-IGF-II measured by standard RIA after size-exclusion acid chromatography. RESULTS The analyses of patients' sera by size-exclusion acid chromatography showed that 68 +/- 19% of IGF-II were present in the pro-IGF-II form, whereas only 18 +/- 4% corresponded to pro-IGF-II in controls. Scanning densitometry of immunoblots showed 67 +/- 16% in the bands corresponding to pro-IGF-II in patients' sera, compared with 27 +/- 9% in controls. The detection sensitivity of tricine-SDS-PAGE method was the same as for size-exclusion chromatography, but the tricine-SDS-PAGE method is quicker and requires smaller amounts of serum. CONCLUSIONS Tricine-SDS-PAGE followed by IGF-II immunoblot analysis provides a rapid, reproducible, and sensitive method for the separation of serum pro-IGF-II from mature IGF-II and is a useful laboratory evaluation of patients with a clinical diagnosis of NICTH.

UI MeSH Term Description Entries
D007003 Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH. Fasting Hypoglycemia,Postabsorptive Hypoglycemia,Postprandial Hypoglycemia,Reactive Hypoglycemia,Hypoglycemia, Fasting,Hypoglycemia, Postabsorptive,Hypoglycemia, Postprandial,Hypoglycemia, Reactive
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D007335 Insulin-Like Growth Factor II A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults. IGF-II,Multiplication-Stimulating Activity,Somatomedin MSA,IGF-2,Insulin Like Growth Factor II,Insulin-Like Somatomedin Peptide II,Multiplication-Stimulating Factor,Somatomedin A,Factor, Multiplication-Stimulating,Insulin Like Somatomedin Peptide II,Multiplication Stimulating Activity,Multiplication Stimulating Factor
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011498 Protein Precursors Precursors, Protein
D002850 Chromatography, Gel Chromatography on non-ionic gels without regard to the mechanism of solute discrimination. Chromatography, Exclusion,Chromatography, Gel Permeation,Chromatography, Molecular Sieve,Gel Filtration,Gel Filtration Chromatography,Chromatography, Size Exclusion,Exclusion Chromatography,Gel Chromatography,Gel Permeation Chromatography,Molecular Sieve Chromatography,Chromatography, Gel Filtration,Exclusion Chromatography, Size,Filtration Chromatography, Gel,Filtration, Gel,Sieve Chromatography, Molecular,Size Exclusion Chromatography
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Farideh Miraki-Moud, and Ashley B Grossman, and Michael Besser, and John P Monson, and Cecilia Camacho-Hübner
Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia.
April 1998, Endocrine journal,
Farideh Miraki-Moud, and Ashley B Grossman, and Michael Besser, and John P Monson, and Cecilia Camacho-Hübner
Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia.
August 2006, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society,
Farideh Miraki-Moud, and Ashley B Grossman, and Michael Besser, and John P Monson, and Cecilia Camacho-Hübner
Serum high molecular weight form of insulin-like growth factor II from patients with non-islet cell tumor hypoglycemia is O-glycosylated.
August 1998, The Journal of clinical endocrinology and metabolism,
Farideh Miraki-Moud, and Ashley B Grossman, and Michael Besser, and John P Monson, and Cecilia Camacho-Hübner
A case of gastric cancer with non-islet cell tumor hypoglycemia detected by insulin-like growth factor II.
August 2010, Pathology international,
Farideh Miraki-Moud, and Ashley B Grossman, and Michael Besser, and John P Monson, and Cecilia Camacho-Hübner
Characterization of insulin-like growth factor II (IGF-II) and IGF binding proteins in patients with non-islet-cell tumor hypoglycemia.
February 1993, Endocrine journal,
Farideh Miraki-Moud, and Ashley B Grossman, and Michael Besser, and John P Monson, and Cecilia Camacho-Hübner
Insulin-like growth factors and non-islet cell tumor hypoglycemia.
September 1993, Metabolism: clinical and experimental,
Farideh Miraki-Moud, and Ashley B Grossman, and Michael Besser, and John P Monson, and Cecilia Camacho-Hübner
Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors.
December 1981, The New England journal of medicine,
Farideh Miraki-Moud, and Ashley B Grossman, and Michael Besser, and John P Monson, and Cecilia Camacho-Hübner
Hypoglycemia associated with non-islet-cell tumor and insulin-like growth factors.
May 1982, The New England journal of medicine,
Farideh Miraki-Moud, and Ashley B Grossman, and Michael Besser, and John P Monson, and Cecilia Camacho-Hübner
Gastric neuroendocrine carcinoma with non-islet cell tumor hypoglycemia associated with enhanced production of insulin-like growth factor II.
January 2013, Internal medicine (Tokyo, Japan),
Farideh Miraki-Moud, and Ashley B Grossman, and Michael Besser, and John P Monson, and Cecilia Camacho-Hübner
Antibodies directed against the E region of pro-insulin-like growth factor-II used to evaluate non-islet cell tumor-induced hypoglycemia.
October 2002, Clinical chemistry,
Copied contents to your clipboard!